Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyAmrinone
Identification
- Name
- Amrinone
- Accession Number
- DB01427
- Type
- Small Molecule
- Groups
- Approved
- Description
Amrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.
- Structure
Structure for DB01427 (Amrinone)
- Synonyms
- Amrinona
- Amrinonum
- Inamrinone
- External IDs
- C01CE01 / WIN 40680 / WIN-40680
- Product Ingredients
Ingredient UNII CAS InChI Key Amrinone lactate I229274Y5B 75898-90-7 DOSIONJFGDSKCQ-UHFFFAOYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Inocor Liq 5mg/ml Liquid 5 mg Intravenous Sanofi 1984-12-31 2000-07-24 Canada 
- International/Other Brands
- Amcoral / Inocor
- Categories
- Amines
- Aminopyridines
- Calcium Channel Blockers
- Cardiac Stimulants Excl. Cardiac Glycosides
- Cardiac Therapy
- Cardiotonic Agents
- Cardiovascular Agents
- Cardiovascular System
- Enzyme Inhibitors
- Membrane Transport Modulators
- Phosphodiesterase 3 Inhibitors
- Phosphodiesterase Inhibitors
- Protective Agents
- Pyridines
- Vasodilator Agents
- UNII
- JUT23379TN
- CAS number
- 60719-84-8
- Weight
- Average: 187.198
Monoisotopic: 187.074561925 - Chemical Formula
- C10H9N3O
- InChI Key
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14)
- IUPAC Name
- 3-amino-5-(pyridin-4-yl)-1,2-dihydropyridin-2-one
- SMILES
- NC1=CC(=CNC1=O)C1=CC=NC=C1
Pharmacology
- Indication
Used in the treatment of congestive heart failure.
- Structured Indications
- Not Available
- Pharmacodynamics
Amrinone is a positive inotropic cardiotonic with vasodilator properties, phosphodiesterase inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
- Mechanism of action
Amrinone is a phosphodiesterase inhibitor (PDE3), resulting in increased cAMP and cGMP which leads to an increase in the calcium influx like that caused by beta-agonists resulting in increased inotropic effect.
Target Actions Organism UcAMP-specific 3',5'-cyclic phosphodiesterase 4B inhibitorHuman UTumor necrosis factor inhibitorHuman AcGMP-inhibited 3',5'-cyclic phosphodiesterase A inhibitorHuman UcAMP-specific 3',5'-cyclic phosphodiesterase 3 Not Available Human - Absorption
- Not Available
- Volume of distribution
- 1.2 L/kg [normal volunteers]
- Protein binding
10 to 49%
- Metabolism
Hepatic.
- Route of elimination
The primary route of excretion in man is via the urine as both inamrinone and several metabolites (N-glycolyl, N-acetate, O-glucuronide and N-glucuronide).
- Half life
5 to 8 hours
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2-HYDROXY-1,4-NAPHTHOQUINONE The therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Amrinone. Experimental 2-mercaptobenzothiazole The therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Amrinone. Vet Approved Alfuzosin The risk or severity of hypotension can be increased when Alfuzosin is combined with Amrinone. Approved, Investigational Amobarbital The metabolism of Amrinone can be increased when combined with Amobarbital. Approved, Illicit Amorolfine The therapeutic efficacy of Amorolfine can be increased when used in combination with Amrinone. Approved, Investigational Amphotericin B The therapeutic efficacy of Amphotericin B can be increased when used in combination with Amrinone. Approved, Investigational Anidulafungin The therapeutic efficacy of Anidulafungin can be increased when used in combination with Amrinone. Approved, Investigational Arotinolol The risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Amrinone. Investigational Artemether The therapeutic efficacy of Artemether can be increased when used in combination with Amrinone. Approved Bafilomycin A1 The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Amrinone. Experimental Barbexaclone The metabolism of Amrinone can be increased when combined with Barbexaclone. Experimental Barbital The metabolism of Amrinone can be increased when combined with Barbital. Illicit Benzoic Acid The therapeutic efficacy of Benzoic Acid can be increased when used in combination with Amrinone. Approved, Investigational Bifonazole The therapeutic efficacy of Bifonazole can be increased when used in combination with Amrinone. Approved, Investigational Brefeldin A The therapeutic efficacy of Brefeldin A can be increased when used in combination with Amrinone. Experimental Bucindolol The risk or severity of hypotension can be increased when Bucindolol is combined with Amrinone. Investigational Bunazosin The risk or severity of hypotension can be increased when Bunazosin is combined with Amrinone. Investigational Butenafine The therapeutic efficacy of Butenafine can be increased when used in combination with Amrinone. Approved Butoconazole The therapeutic efficacy of Butoconazole can be increased when used in combination with Amrinone. Approved Calcium Acetate The therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium Acetate. Approved, Investigational Calcium Chloride The therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium Chloride. Approved Calcium Citrate The therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium Citrate. Approved Calcium glubionate The therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium glubionate. Approved Calcium Gluceptate The therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium Gluceptate. Approved Calcium gluconate The therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium gluconate. Approved, Vet Approved Calcium lactate The therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium lactate. Approved, Experimental, Investigational, Vet Approved Calcium lactate gluconate The therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium lactate gluconate. Experimental Calcium levulinate The therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium levulinate. Approved, Experimental Calcium pangamate The therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium pangamate. Experimental Calcium Phosphate The therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium Phosphate. Approved Candicidin The therapeutic efficacy of Candicidin can be increased when used in combination with Amrinone. Withdrawn Capric acid The therapeutic efficacy of Capric acid can be increased when used in combination with Amrinone. Experimental Carvedilol The risk or severity of hypotension can be increased when Carvedilol is combined with Amrinone. Approved, Investigational Casein The therapeutic efficacy of Amrinone can be decreased when used in combination with Casein. Approved Caspofungin The therapeutic efficacy of Caspofungin can be increased when used in combination with Amrinone. Approved Cerulenin The therapeutic efficacy of Cerulenin can be increased when used in combination with Amrinone. Approved Chloroxine The therapeutic efficacy of Chloroxine can be increased when used in combination with Amrinone. Approved Ciclopirox The therapeutic efficacy of Ciclopirox can be increased when used in combination with Amrinone. Approved, Investigational Cimetidine The serum concentration of Amrinone can be increased when it is combined with Cimetidine. Approved, Investigational Clopidogrel The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Amrinone. Approved Clotrimazole The therapeutic efficacy of Clotrimazole can be increased when used in combination with Amrinone. Approved, Vet Approved Cordycepin The therapeutic efficacy of Cordycepin can be increased when used in combination with Amrinone. Investigational Cyclosporine The therapeutic efficacy of Cyclosporine can be increased when used in combination with Amrinone. Approved, Investigational, Vet Approved Dichlorophene The therapeutic efficacy of Dichlorophene can be increased when used in combination with Amrinone. Vet Approved Doxazosin The risk or severity of hypotension can be increased when Doxazosin is combined with Amrinone. Approved Econazole The therapeutic efficacy of Econazole can be increased when used in combination with Amrinone. Approved Efavirenz The serum concentration of Amrinone can be decreased when it is combined with Efavirenz. Approved, Investigational Efinaconazole The therapeutic efficacy of Efinaconazole can be increased when used in combination with Amrinone. Approved Fenticonazole The therapeutic efficacy of Fenticonazole can be increased when used in combination with Amrinone. Experimental Fluconazole The therapeutic efficacy of Fluconazole can be increased when used in combination with Amrinone. Approved, Investigational Flucytosine The therapeutic efficacy of Flucytosine can be increased when used in combination with Amrinone. Approved, Investigational Flutrimazole The therapeutic efficacy of Flutrimazole can be increased when used in combination with Amrinone. Experimental Glyphosate The therapeutic efficacy of Glyphosate can be increased when used in combination with Amrinone. Experimental Griseofulvin The therapeutic efficacy of Griseofulvin can be increased when used in combination with Amrinone. Approved, Investigational, Vet Approved Hachimycin The therapeutic efficacy of Hachimycin can be increased when used in combination with Amrinone. Experimental Haloprogin The therapeutic efficacy of Haloprogin can be increased when used in combination with Amrinone. Approved, Withdrawn Hexetidine The therapeutic efficacy of Hexetidine can be increased when used in combination with Amrinone. Approved, Investigational Hexobarbital The metabolism of Amrinone can be increased when combined with Hexobarbital. Approved Indoramin The risk or severity of hypotension can be increased when Indoramin is combined with Amrinone. Withdrawn Isoconazole The therapeutic efficacy of Isoconazole can be increased when used in combination with Amrinone. Approved Itraconazole The therapeutic efficacy of Itraconazole can be increased when used in combination with Amrinone. Approved, Investigational Ketoconazole The therapeutic efficacy of Ketoconazole can be increased when used in combination with Amrinone. Approved, Investigational Labetalol The risk or severity of hypotension can be increased when Labetalol is combined with Amrinone. Approved Magnesium hydroxide The risk or severity of hypotension and neuromuscular blockade can be increased when Amrinone is combined with Magnesium hydroxide. Approved, Investigational Magnesium oxide The risk or severity of hypotension and neuromuscular blockade can be increased when Amrinone is combined with Magnesium oxide. Approved Magnesium salicylate The risk or severity of hypotension and neuromuscular blockade can be increased when Amrinone is combined with Magnesium salicylate. Approved Magnesium sulfate The risk or severity of hypotension and neuromuscular blockade can be increased when Amrinone is combined with Magnesium sulfate. Approved, Investigational, Vet Approved Mepartricin The therapeutic efficacy of Mepartricin can be increased when used in combination with Amrinone. Experimental Methohexital The metabolism of Amrinone can be increased when combined with Methohexital. Approved Methylphenobarbital The metabolism of Amrinone can be increased when combined with Methylphenobarbital. Approved Mevastatin The therapeutic efficacy of Mevastatin can be increased when used in combination with Amrinone. Experimental Micafungin The therapeutic efficacy of Micafungin can be increased when used in combination with Amrinone. Approved, Investigational Miconazole The therapeutic efficacy of Miconazole can be increased when used in combination with Amrinone. Approved, Investigational, Vet Approved Miltefosine The therapeutic efficacy of Miltefosine can be increased when used in combination with Amrinone. Approved, Investigational Monensin The therapeutic efficacy of Monensin can be increased when used in combination with Amrinone. Vet Approved Myxothiazol The therapeutic efficacy of Myxothiazol can be increased when used in combination with Amrinone. Experimental Nafcillin The therapeutic efficacy of Amrinone can be decreased when used in combination with Nafcillin. Approved, Investigational Naftifine The therapeutic efficacy of Naftifine can be increased when used in combination with Amrinone. Approved Natamycin The therapeutic efficacy of Natamycin can be increased when used in combination with Amrinone. Approved Nifuratel The therapeutic efficacy of Nifuratel can be increased when used in combination with Amrinone. Experimental Nikkomycin Z The therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Amrinone. Investigational Nitroprusside Amrinone may increase the hypotensive activities of Nitroprusside. Approved, Investigational Nitroxoline The therapeutic efficacy of Nitroxoline can be increased when used in combination with Amrinone. Approved Nystatin The therapeutic efficacy of Nystatin can be increased when used in combination with Amrinone. Approved, Vet Approved Omoconazole The therapeutic efficacy of Omoconazole can be increased when used in combination with Amrinone. Experimental Oxiconazole The therapeutic efficacy of Oxiconazole can be increased when used in combination with Amrinone. Approved Pafuramidine The therapeutic efficacy of Pafuramidine can be increased when used in combination with Amrinone. Investigational Pentamidine The therapeutic efficacy of Pentamidine can be increased when used in combination with Amrinone. Approved, Investigational Pentobarbital The metabolism of Amrinone can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Phenobarbital The metabolism of Amrinone can be increased when combined with Phenobarbital. Approved, Investigational Posaconazole The therapeutic efficacy of Posaconazole can be increased when used in combination with Amrinone. Approved, Investigational, Vet Approved Prazosin The risk or severity of hypotension can be increased when Prazosin is combined with Amrinone. Approved Primidone The metabolism of Amrinone can be increased when combined with Primidone. Approved, Vet Approved Pyrrolnitrin The therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Amrinone. Experimental Radicicol The therapeutic efficacy of Radicicol can be increased when used in combination with Amrinone. Experimental Rifabutin The risk or severity of hypotension can be increased when Rifabutin is combined with Amrinone. Approved, Investigational Rifampicin The risk or severity of hypotension can be increased when Rifampicin is combined with Amrinone. Approved Rifapentine The risk or severity of hypotension can be increased when Rifapentine is combined with Amrinone. Approved, Investigational Rifaximin The risk or severity of hypotension can be increased when Rifaximin is combined with Amrinone. Approved, Investigational Salicylhydroxamic Acid The therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Amrinone. Experimental Salicylic acid The therapeutic efficacy of Salicylic acid can be increased when used in combination with Amrinone. Approved, Investigational, Vet Approved Secobarbital The metabolism of Amrinone can be increased when combined with Secobarbital. Approved, Vet Approved Sertaconazole The therapeutic efficacy of Sertaconazole can be increased when used in combination with Amrinone. Approved, Investigational Silodosin The risk or severity of hypotension can be increased when Silodosin is combined with Amrinone. Approved Sinefungin The therapeutic efficacy of Sinefungin can be increased when used in combination with Amrinone. Experimental Sirolimus The therapeutic efficacy of Sirolimus can be increased when used in combination with Amrinone. Approved, Investigational Sulconazole The therapeutic efficacy of Sulconazole can be increased when used in combination with Amrinone. Approved Tamsulosin The risk or severity of hypotension can be increased when Tamsulosin is combined with Amrinone. Approved, Investigational Tavaborole The therapeutic efficacy of Tavaborole can be increased when used in combination with Amrinone. Approved, Investigational Terazosin The risk or severity of hypotension can be increased when Terazosin is combined with Amrinone. Approved Terbinafine The therapeutic efficacy of Terbinafine can be increased when used in combination with Amrinone. Approved, Investigational, Vet Approved Terconazole The therapeutic efficacy of Terconazole can be increased when used in combination with Amrinone. Approved Thiamylal The metabolism of Amrinone can be increased when combined with Thiamylal. Approved, Vet Approved Thiopental The metabolism of Amrinone can be increased when combined with Thiopental. Approved, Vet Approved Thymol The therapeutic efficacy of Thymol can be increased when used in combination with Amrinone. Approved Tioconazole The therapeutic efficacy of Tioconazole can be increased when used in combination with Amrinone. Approved Tolciclate The therapeutic efficacy of Tolciclate can be increased when used in combination with Amrinone. Experimental Tolnaftate The therapeutic efficacy of Tolnaftate can be increased when used in combination with Amrinone. Approved, Investigational, Vet Approved Trimazosin The risk or severity of hypotension can be increased when Trimazosin is combined with Amrinone. Experimental Trimetrexate The therapeutic efficacy of Trimetrexate can be increased when used in combination with Amrinone. Approved, Investigational Urapidil The risk or severity of hypotension can be increased when Urapidil is combined with Amrinone. Investigational Voriconazole The therapeutic efficacy of Voriconazole can be increased when used in combination with Amrinone. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Lesher,G.Y. and Opalka, C.J.; US. Patent 4,004,012; January 18,1977; assigned to Sterling Drug Inc. Lesher, G.Y. and Opalka, C.J.; U.S. Patent 4,107,315; August 15,1978; assigned to Sterling Drug Inc.
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015496
- KEGG Drug
- D00231
- KEGG Compound
- C13594
- PubChem Compound
- 3698
- PubChem Substance
- 46504647
- ChemSpider
- 3570
- BindingDB
- 34651
- ChEBI
- 2686
- ChEMBL
- CHEMBL12856
- Therapeutic Targets Database
- DAP001392
- PharmGKB
- PA164746803
- Wikipedia
- Amrinone
- ATC Codes
- C01CE01 — Amrinone
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Bedford Labs
- Ben Venue Laboratories Inc.
- Taylor Pharmaceuticals
- Dosage forms
Form Route Strength Liquid Intravenous 5 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 294-297 Lesher,G.Y. and Opalka, C.J.; US. Patent 4,004,012; January 18,1977; assigned to Sterling Drug Inc. Lesher, G.Y. and Opalka, C.J.; U.S. Patent 4,107,315; August 15,1978; assigned to Sterling Drug Inc. - Predicted Properties
Property Value Source Water Solubility 5.6 mg/mL ALOGPS logP 0.27 ALOGPS logP -0.57 ChemAxon logS -1.5 ALOGPS pKa (Strongest Acidic) 11.01 ChemAxon pKa (Strongest Basic) 4.87 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 68.01 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 53.89 m3·mol-1 ChemAxon Polarizability 18.94 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9522 Blood Brain Barrier + 0.9525 Caco-2 permeable + 0.8867 P-glycoprotein substrate Non-substrate 0.6469 P-glycoprotein inhibitor I Non-inhibitor 0.9338 P-glycoprotein inhibitor II Non-inhibitor 0.9946 Renal organic cation transporter Non-inhibitor 0.9258 CYP450 2C9 substrate Non-substrate 0.8642 CYP450 2D6 substrate Non-substrate 0.8389 CYP450 3A4 substrate Non-substrate 0.6443 CYP450 1A2 substrate Inhibitor 0.9107 CYP450 2C9 inhibitor Inhibitor 0.5328 CYP450 2D6 inhibitor Non-inhibitor 0.9651 CYP450 2C19 inhibitor Inhibitor 0.8994 CYP450 3A4 inhibitor Non-inhibitor 0.6534 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5933 Ames test Non AMES toxic 0.8492 Carcinogenicity Non-carcinogens 0.9116 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.9371 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9923 hERG inhibition (predictor II) Non-inhibitor 0.7418
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-00lr-3900000000-f6b4ee8cb119f30be206
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as bipyridines and oligopyridines. These are organic compounds containing two pyridine rings linked to each other.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Bipyridines and oligopyridines
- Direct Parent
- Bipyridines and oligopyridines
- Alternative Parents
- Pyridinones / Dihydropyridines / Aminopyridines and derivatives / Heteroaromatic compounds / Lactams / Azacyclic compounds / Primary amines / Organopnictogen compounds / Organooxygen compounds / Organic oxides show 1 more
- Substituents
- Bipyridine / Aminopyridine / Dihydropyridine / Pyridinone / Hydropyridine / Heteroaromatic compound / Lactam / Azacycle / Amine / Primary amine show 8 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Metal ion binding
- Specific Function
- Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging f...
- Gene Name
- PDE4B
- Uniprot ID
- Q07343
- Uniprot Name
- cAMP-specific 3',5'-cyclic phosphodiesterase 4B
- Molecular Weight
- 83342.695 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Tumor necrosis factor receptor binding
- Specific Function
- Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct ac...
- Gene Name
- TNF
- Uniprot ID
- P01375
- Uniprot Name
- Tumor necrosis factor
- Molecular Weight
- 25644.15 Da
References
- Kumar A, Kosuri R, Kandula P, Dimou C, Allen J, Parrillo JE: Effects of epinephrine and amrinone on contractility and cyclic adenosine monophosphate generation of tumor necrosis factor alpha-exposed cardiac myocytes. Crit Care Med. 1999 Feb;27(2):286-92. [PubMed:10075051]
- Bergman MR, Kao RH, McCune SA, Holycross BJ: Myocardial tumor necrosis factor-alpha secretion in hypertensive and heart failure-prone rats. Am J Physiol. 1999 Aug;277(2 Pt 2):H543-50. [PubMed:10444479]
- Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R: Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther. 2002 Feb;300(2):559-66. [PubMed:11805217]
- Marx D, Tassabehji M, Heer S, Huttenbrink KB, Szelenyi I: Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids. Pulm Pharmacol Ther. 2002;15(1):7-15. [PubMed:11969359]
- Giroir BP, Beutler B: Effect of amrinone on tumor necrosis factor production in endotoxic shock. Circ Shock. 1992 Mar;36(3):200-7. [PubMed:1611705]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Metal ion binding
- Specific Function
- Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
- Gene Name
- PDE3A
- Uniprot ID
- Q14432
- Uniprot Name
- cGMP-inhibited 3',5'-cyclic phosphodiesterase A
- Molecular Weight
- 124978.06 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kobayashi T, Sugawara Y, Ohkubo T, Imamura H, Makuuchi M: Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8. [PubMed:12076859]
- Ko Y, Morita K, Nagahori R, Kinouchi K, Shinohara G, Kagawa H, Hashimoto K: Myocardial cyclic AMP augmentation with high-dose PDEIII inhibitor in terminal warm blood cardioplegia. Ann Thorac Cardiovasc Surg. 2009 Oct;15(5):311-7. [PubMed:19901885]
- Kucuk C, Akcan A, Akyyldyz H, Akgun H, Muhtaroglu S, Sozuer E: Effects of amrinone in an experimental model of hepatic ischemia-reperfusion injury. J Surg Res. 2009 Jan;151(1):74-9. doi: 10.1016/j.jss.2008.02.008. Epub 2008 Mar 13. [PubMed:18468627]
4. cAMP-specific 3',5'-cyclic phosphodiesterase 3
Unknown
References
- Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR: Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res. 1987 Oct;61(4):539-47. [PubMed:2820608]
Drug created on July 24, 2007 06:34 / Updated on March 02, 2018 05:18